Approved MAPK pathway-targeted therapies for melanoma such as the BRAF inhibitor vemurafenib, the MAPK inhibitor dabrafenib, and the MEK inhibitor trametinib caused an inhibition of anti-GD2 CAR T cells in vitro at high concentrations [102]. This evidence concerns the gene MAP2K7 and melanoma.